MXCT
MaxCyte IncKey Statistics
About MaxCyte Inc
MaxCyte Inc. (MXCT) is a pioneering company in cell-engineering, known for its proprietary Flow Electroporation® technology that facilitates the efficient and scalable delivery of nucleic acids and proteins across various cell types. Serving a diverse and prestigious clientele, including leading biopharmaceutical firms and renowned research institutions, MaxCyte is strategically positioned to leverage the burgeoning cell and gene therapy market. The company's advanced platforms are integral to the development of innovative cell-based therapies and vaccines, thus addressing the rising global demand for transformative medical solutions. With a strong commitment to healthcare advancements, MaxCyte is well-equipped to enhance patient outcomes while seizing significant market opportunities.
Fundamentals
| Revenue (TTM) | $32.29M |
| Gross Profit (TTM) | $25.99M |
| EBITDA | $-34.16M |
| Operating Margin | -64.10% |
| Return on Equity | -21.30% |
| Return on Assets | -11.30% |
| Revenue/Share (TTM) | $0.30 |
| Book Value | $1.57 |
| Price-to-Book | 0.65 |
| Price-to-Sales (TTM) | 3.45 |
| EV/Revenue | 0.616 |
| EV/EBITDA | -11.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -7.10% |
| Shares Outstanding | $107.12M |
| Float | $97.67M |
| % Insiders | 1.37% |
| % Institutions | 67.93% |
Historical Volatility
Volatility is currently expanding